6 terminated, 3 active not recruiting, 2 recruiting, 1 completed. 6 Phase 1, 6 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Terminated 5, Recruiting 1 |
| Phase 2 | 6 | Active not recruiting 2, Recruiting 2, Completed 1, Terminated 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Cartesian Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Descartes-08 in Autoantibody Myositis Descartes-08, Placebo - Antisynthetase Syndrome | Phase 2 | Recruiting | Cartesian Therapeutics | 60 | 2026-04-28 | 2026-08-17 |
| Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders Descartes-08 - Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV) | Phase 1 / Phase 2 | Recruiting | Cartesian Therapeutics | 50 | 2026-01-14 | 2026-07-27 |
| Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis Decartes-08, Placebo Drug - Myasthaenia Gravis | Phase 3 | Active not recruiting | Cartesian Therapeutics | 128 | 2025-05-06 | 2026-09-01 |
| Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma Descartes-15 - Refractory Multiple Myeloma, Relapsed Multiple Myeloma | Phase 1 | Terminated | Cartesian Therapeutics | 4 | 2024-06-19 | 2025-11-24 |
| Descartes-08 for Patients With Systemic Lupus Erythematosus Descartes-08 - Systemic Lupus Erythematosus (SLE) | Phase 2 | Active not recruiting | Cartesian Therapeutics | 6 | 2024-02-12 | 2026-03-27 |
| Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy Descartes 08 - Myeloma Multiple | Phase 2 | Terminated | Cartesian Therapeutics | 13 | 2021-12-01 | 2024-10-08 |
| Descartes-25 in Relapsed/Refractory Multiple Myeloma Descartes-25 - Multiple Myeloma, Relapse Multiple Myeloma | Phase 1 | Terminated | Cartesian Therapeutics | 9 | 2021-11-25 | 2024-11-12 |
| Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy Descartes 11 - Multiple Myeloma | Phase 2 | Completed | Cartesian Therapeutics | 5 | 2021-02-24 | 2024-12-03 |
| Study of Descartes-30 in Acute Respiratory Distress Syndrome Descartes 30 - Acute Respiratory Distress Syndrome, Covid19 | Phase 1 | Terminated | Cartesian Therapeutics | 12 | 2021-02-23 | 2024-10-29 |
| Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) Descartes-08 - Myasthenia Gravis, Generalized | Phase 2 | Active not recruiting | Cartesian Therapeutics | 30 | 2019-12-04 | 2026-08-14 |
| Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma Descartes-11, Fludarabine, Cyclophosphamide - Multiple Myeloma | Phase 1 | Terminated | Cartesian Therapeutics | 20 | 2019-08-01 | 2025-05-15 |
| Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma Descartes-08, Fludarabine, Cyclophosphamide - Multiple Myeloma | Phase 1 | Terminated | Cartesian Therapeutics | 32 | 2018-03-08 | 2024-07-01 |
Multiple Myeloma (6) · Myasthenia Gravis (2) · Neoplasms, Plasma Cell (2) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Antisynthetase syndrome (1) · COVID-19 (1) · Dermatomyositis (1) · Lupus Erythematosus, Systemic (1) · Myositis (1) · Recurrence (1) · Respiratory Distress Syndrome (1)
Cyclophosphamide (2) · fludarabine (2) · Immunotherapy, Adoptive (1)
United States (12) · Canada (2) · Turkey (Türkiye) (2) · Italy (1) · Poland (1) · Serbia (1) · Spain (1) · United Kingdom (1)
PMID 34182226, PMID 35285981, PMID 37353270, PMID 37353278, PMID 41514038, PMID 41514039
R44CA221432 (1), R44HL158446 (1)